RxDoctor Payments Data

Jennifer Holcombe

Nurse Practitioner · Cropwell, ALNPI 1265918163

Payments from drug & device makers

$2,509in general payments, 2019–2025

Across 156 payments — averaging $16.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Scilex Pharmaceuticals Inc.$851
  • Collegium Pharmaceutical, Inc.$478
  • Boston Scientific$332
  • Forte Bio-pharma LLC$208
  • Biosense Webster, Inc.$147
  • Novo Nordisk$122
  • plus $371 from 11 others

What the payments were for

  • Food & beverage$2,48899%
  • Education$211%
  • Gifts$00%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,509 in reported general payments places this provider in the 80th percentile of 1,505 nurse practitioner providers in Alabama.

See all nurse practitioner providers in Alabama

Medicare billing

Part B allowed, 2024
$130,844
Medicare patients
338
Services billed
3,119

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl245$54,475
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen993$37,401
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,169$31,177
LinzessLinaclotide41$23,637
Diclofenac Sodium186$20,702
ZtlidoLidocaine26$14,178
Buprenorphine41$13,231
BelbucaBuprenorphine Hcl14$13,133
Fluocinonide119$12,140
Gabapentin1,001$11,787
MovantikNaloxegol Oxalate29$11,505
Diflorasone Diacetate15$10,581
Pregabalin481$9,566
Methocarbamol393$4,903
Naloxone Hcl66$4,605

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Hikma Pharmaceuticals USABuprenorphine-Naloxone, Buprenorphine, Buprenorphine Hcl$21$71,328344 claims
Scilex Pharmaceuticals Inc.Ztlido$851$14,17826 claims
Collegium Pharmaceutical, Inc.Belbuca$478$13,13314 claims
Redhill Biopharma Inc.Movantik$59$11,50529 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,505 nurse practitioner providers in Alabama.

Other nurse practitioner in Cropwell

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →